KEY POINTS:
From today, New Zealand women will be eligible to receive nine weeks of funded Herceptin to treat HER2-positive breast cancer.
Pharmac said about 350 women a year would benefit from the funding.
In Australia, Canada and Britain, a 52-week course of Herceptin is fully funded.
